Drugs / BEAM-301
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06735755 | Dec 2024 → Dec 2027 expected | glycogen storage disease due to glucose-6-phosphatase deficiency type IA | Beam Therapeutics Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2024-08-06 | Beam Therapeutics Inc. | Regulatory Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results beamtx.com ↗
In our genetic disease franchise, we’re pleased to announce the clearance of our U.S. investigational new drug (IND) application for BEAM-301, our first U.S. in vivo regulatory filing. |
| 2023-10-25 | Beam Therapeutics Inc. | Results Beam Therapeutics Presents Preclinical Data Highlighting Utility and Durability of BEAM-301 to Correct a Glycogen Storage Disease Type I Deficiency Disease-Causing Mutation at ESGCT beamtx.com ↗
today reported new preclinical data demonstrating the ability of its in vivo drug candidate, BEAM-301, to directly correct the R83C mutation, one of the primary disease-causing mutations of glycogen storage disease type Ia (GSDIa). |
| 2022-05-02 | Beam Therapeutics Inc. | Results Beam Therapeutics to Present New Preclinical Data from Base Editing Pipeline at ASGCT 25th Annual Meeting beamtx.com ↗
Single, systemic administration of BEAM-301 mitigates fasting hypoglycemia and restores metabolic function |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-08-06 | Beam Therapeutics Inc. | Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results beamtx.com ↗ |
| 2023-10-25 | Beam Therapeutics Inc. | Beam Therapeutics Presents Preclinical Data Highlighting Utility and Durability of BEAM-301 to Correct a Glycogen Storage Disease Type I Deficiency Disease-Causing Mutation at ESGCT beamtx.com ↗ |
| 2022-05-02 | Beam Therapeutics Inc. | Beam Therapeutics to Present New Preclinical Data from Base Editing Pipeline at ASGCT 25th Annual Meeting beamtx.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BEAM-301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06735755 ↗ |
| Action | Restore | “resulting in restoration of G6Pase-α catalytic activity” NCT06735755 ↗ |
| Route | Intravenous | “for intravenous (IV) administration” NCT06735755 ↗ |
| Target | G6PC1 | “BEAM-301 is designed to correct the G6PC1 c.247C\>T allele” NCT06735755 ↗ |